Avadel Pharmaceuticals: 从2028年3月1日起,Lumryz在任何未来FDA批准的适应症销售将适用10%的净销售额特许权使用费
Avadel Pharmaceuticals: 从2028年3月1日起,Lumryz在任何未来FDA批准的适应症销售将适用10%的净销售额特许权使用费
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.